Yahoo · Sep 16, 2026
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
AN
NASDAQ · ANIK
Anika Therapeutics, Inc.
Healthcare · Medical - Devices
$20.84
Up+$0.12 (+0.58%)
Updated Sep 17, 2026, 6:34 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 207.09M
- P/E ratio
- -18.84
- Dividend yield
- 0.00%
- 52-week range
- $8.67 – $22.88
- Volume
- 50.58K
- Avg. volume
- 156.61K
Price performance
ANIK price history
1M range · 20 trading sessions · Daily adjusted prices
ANIK closed at $20.84 after 20 trading sessions, down 1.98% for the selected period.
- Last close
- $20.84
- Period change
- -1.98%
- Period low
- $20.81
- Period high
- $21.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $20.79 | $21.16 | $20.755 | $20.84 | 50.58K |
| Sep 15, 2026 | $21.19 | $21.19 | $20.635 | $20.91 | 81.74K |
| Sep 14, 2026 | $20.86 | $21.38 | $20.81 | $21.19 | 49.57K |
| Sep 11, 2026 | $21.25 | $21.29 | $20.73 | $20.86 | 70.32K |
| Sep 10, 2026 | $20.88 | $20.99 | $20.575 | $20.99 | 48.41K |
| Sep 9, 2026 | $21.01 | $21.31 | $20.6913 | $20.88 | 70.5K |
| Sep 8, 2026 | $20.58 | $21.205 | $20.16 | $21.04 | 74.83K |
| Sep 4, 2026 | $21.01 | $21.50 | $20.76 | $20.81 | 96.36K |
| Sep 3, 2026 | $21.56 | $21.56 | $20.85 | $21.00 | 57.72K |
| Sep 2, 2026 | $21.06 | $21.66 | $20.96 | $21.55 | 77.75K |
| Sep 1, 2026 | $20.69 | $21.44 | $20.69 | $21.11 | 90.13K |
| Aug 31, 2026 | $20.97 | $21.30 | $20.13 | $20.87 | 144.61K |
| Aug 28, 2026 | $20.95 | $21.44 | $20.80 | $21.10 | 98.94K |
| Aug 27, 2026 | $21.51 | $21.97 | $20.80 | $20.84 | 171.47K |
| Aug 26, 2026 | $21.29 | $21.7999 | $20.845 | $21.68 | 90.15K |
| Aug 25, 2026 | $21.43 | $21.9189 | $21.35 | $21.40 | 73.46K |
| Aug 24, 2026 | $22.35 | $22.525 | $21.13 | $21.34 | 124.76K |
| Aug 21, 2026 | $21.38 | $22.32 | $21.0101 | $21.78 | 340.43K |
| Aug 20, 2026 | $21.15 | $21.65 | $21.10 | $21.34 | 89.34K |
| Aug 19, 2026 | $21.88 | $22.05 | $21.25 | $21.26 | 80.21K |
Latest ANIK news
The latest Smart Investors Daily articles mentioning ANIK.
Stock researchCompany · Overview
ANIK research
Overview
Company profile and research snapshot.
Company profile
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | B. Riley Securities | Buy | — |
| Feb 27, 2026 | Barrington Research | Outperform | — |
| Jan 9, 2026 | Barrington Research | Outperform | — |
| Nov 6, 2025 | Barrington Research | Outperform | — |
| Sep 23, 2025 | Barrington Research | Outperform | — |
News briefing
Generated Sep 17, 2026, 3:05 PM
Why Is ANIK Up Today?
Anika Therapeutics (ANIK) gained 1.06% today, reflecting modest positive momentum in the broader market. While the day's gain appears modest, recent regulatory developments in the biotech sector are providing some tailwinds to sentiment around specialty pharmaceutical companies.
Bottom line: Anika Therapeutics' modest 1.06% gain today appears driven by positive sentiment in the biotech sector rather than company-specific news, with recent FDA regulatory progress in rare diseases lifting the broader specialty pharmaceutical space. Investors should use this period to evaluate Anika's fundamental business performance, pipeline strength, and competitive positioning, while remaining alert for upcoming catalysts that could provide more material price drivers. The lack of direct company news suggests caution against reading too much into today's move.
Yahoo · Sep 9, 2026
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Yahoo · Sep 9, 2026
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Yahoo · Sep 4, 2026
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
